Fairvalue-Calculator Fairvalue-Calculator
EN DE

PT Ikapharmindo Putramas Tbk (IKPM) Fair Value & Analysis

Healthcare · ID · Market cap 303B IDR

Price190.00 IDR
Fair Value201.43 IDR
Upside+6.0%
Quality91/100
Evidence: Low Range 149.38 IDR – 253.49 IDR

Fair value as of: Jun 25, 2026

Analysis

PT Ikapharmindo Putramas Tbk (IKPM) currently trades at 190.00 IDR, while our model-based Fair Value estimate is 201.43 IDR — implying the stock looks roughly 6.0% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

PT Ikapharmindo Putramas Tbk engages in the research and development, manufacturing, and marketing of pharmaceutical products in Indonesia. It operates through three segments: Non Pharma, Pharma, and Contract Manufacturing. The company offers prescription medicines in various areas, including neurology, psychiatry, dermatology, nephrology, gastroenterology, and nutraceuticals; and pharmaceuticals, vitamins, and over-the-counter products. It also provides hair and baby care products. PT Ikapharmindo Putramas Tbk was founded in 1978 and is headquartered in Jakarta Timur, Indonesia. PT Ikapharmindo Putramas Tbk is a subsidiary of PT Ikapharma Inti Mas.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is PT Ikapharmindo Putramas Tbk (IKPM) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 201.43 IDR versus a price of 190.00 IDR — about +6% (undervalued). Model-based estimate, not financial advice.
What is the fair value of IKPM?
Our 21-model fair value for PT Ikapharmindo Putramas Tbk is 201.43 IDR (as of Jun 25, 2026), built from audited fundamentals. The current price is 190.00 IDR.
What is the quality score of IKPM?
PT Ikapharmindo Putramas Tbk has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.